In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dipropylamine, N-ethyl-3,3'-diphenyl-, citrate Drug Master File in Korea (Dipropylamine, N-ethyl-3,3'-diphenyl-, citrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dipropylamine, N-ethyl-3,3'-diphenyl-, citrate. The MFDS reviews the Dipropylamine, N-ethyl-3,3'-diphenyl-, citrate KDMF as part of the drug registration process and uses the information provided in the Dipropylamine, N-ethyl-3,3'-diphenyl-, citrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dipropylamine, N-ethyl-3,3'-diphenyl-, citrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dipropylamine, N-ethyl-3,3'-diphenyl-, citrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dipropylamine, N-ethyl-3,3'-diphenyl-, citrate suppliers with KDMF on PharmaCompass.